In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

O’Hare, Thomas; K. Walters, Denise; P. Stoffregen, Eric; Jia, Taiping; W. Manley, Paul; Mestan, Jürgen; W. Cowan‐Jacob, Sandra; Y. Lee, Francis; C. Heinrich, Michael; W. Deininger, Michael; Druker, Brian

doi:10.1158/0008-5472.can-05-0259

Public

In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

Published in Cancer Research • Jun 1, 2005

Authors:

Thomas O’Hare

Denise K. Walters

Eric P. Stoffregen

Abstract

Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mech...

Subject

Imatinib

Tyrosine kinase

Chronic myelogenous leukemia

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!